Market Overview

Investigation Report on China's Levofloxacin (Daiichi Pharmaceutical) Market: 2018-2022 - ResearchAndMarkets.com

Share:

The "Investigation
Report on China's Levofloxacin Market, 2018-2022"
report has
been added to ResearchAndMarkets.com's offering.

Currently, fluoroquinolones are second only to cephalosporins and
penicillins on the antibacterial market. Levofloxacin, a
third-generation fluoroquinolone, was developed by Daiichi
Pharmaceutical Co., Ltd. (merged with Sankyo Co., Ltd. into "Daiichi
Sankyo" in 2005) and first marketed in Japan in 1994.

In 1995, Levofloxacin APIs and tablets manufactured by Daiichi
Pharmaceutical Co., Ltd. were admitted to the Chinese market. After
that, Daiichi Pharmaceutical Co., Ltd. established its Chinese
subsidiary Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. with an
investment of USD 50 million. The subsidiary produces Levofloxacin
preparations in China with the APIs from its parent company.

The Levofloxacin tablets produced in China were launched in 1996 under
the trade name Cravit. At that time, the retail price was about 7
CNY/tablet. Effective and inexpensive, Cravit saw its sales value rising
on the Chinese market. Later, some Chinese companies developed generic
Levofloxacin, and extended the dosage forms from tablets to injections,
capsules, gels, etc.

According to market research, in 1998 when it
had been launched in China for over one year, Levofloxacin became one of
the top 100 drugs by sales value, and then showed an upward trend. The
sales value of Levofloxacin declined from 2016 to 2017 after it reached
CNY 1.23 billion in 2015.

In 2017, China's Levofloxacin market was dominated by Daiichi Sankyo
Pharmaceutical (Beijing) Co., Ltd., Yangtze River Pharmaceutical (Group)
Co., Ltd., China Resources Double-Crane Pharmaceutical Co., Ltd., Santen
Pharmaceutical Co., Ltd., and Zhejiang Medicine Co., Ltd. Xinchang
Pharmaceutical Factory.

By sales value, Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd.
captured a market share of 29.1%. The injections, tablets, and eye drops
accounted for about 63%, 20% and 13.7% respectively of China's
Levofloxacin market. The other dosage forms had a small market share.

As environmental pollution and population aging intensify in China,
there will be higher incidences of the main indications for
Levofloxacin, for example, respiratory infection, urinary infection and
intestinal infection. It is expected that China's Levofloxacin market
will still have some growth potential from 2018 to 2022.

Companies Profiled

  • China Resources Double-Crane Pharmaceutical Co. Ltd.
  • Daiichi Sankyo Pharmaceutical (Beijing) Co. Ltd. (Cravit)
  • Santen Pharmaceutical Co. Ltd.
  • Xinchang Pharmaceutical Factory
  • Yangtze River Pharmaceutical (Group) Co. Ltd. (Zuoke)
  • Zhejiang Medicine Co. Ltd.
  • Xinchang Pharmaceutical Factory (Lailixin)

Topics Covered

  • Development environment of Levofloxacin in China
  • Market size of Levofloxacin in China
  • Competitive landscape of China's Levofloxacin market
  • Prices of Levofloxacin in China
  • Prospect of China's Levofloxacin market from 2018 to 2022

List of Chapters

1 Relevant Concepts of Levofloxacin

2 Sales of Levofloxacin in China, 2013-2017

3 Analysis on Major Levofloxacin Manufacturers in China, 2013-2017

4 Prices of Levofloxacin in China, 2017-2018

5 Prospects of China's Levofloxacin Market, 2018-2022

For more information about this report visit https://www.researchandmarkets.com/research/hmjxl3/investigation?w=4

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com